O
OraSure Technologies, Inc. (OSUR)
NMS – Real vaqt narxi. Valyuta: USD
4.46
+0.05 (1.13%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.41
-0.05 (-1.12%)
Bozordan keyin: Jun 26, 2026, 7:07 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
4.46
+0.05 (1.13%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.41
-0.05 (-1.12%)
Bozordan keyin: Jun 26, 2026, 7:07 PM EDT
OraSure Technologies, Inc. hamda uning sho'ba korxonalari Qo'shma Shtatlar, Yevropa, Afrika va xalqaro miqyosda diagnostika mahsulotlari va namunalar to'plash moslamalarini ishlab chiqadi, ishlab chiqaradi, sotadi va tarqatadi. U O'zbekistonda O'zbekistonda OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test (xalqaro), OraQuick HCV rapid antibody test va self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test va OIV-1 antitelalari uchun OraSure og'iz suyuqligini to'plash moslamasini taklif etadi; Intercept giyohvandlikni tekshirish tizimlari; immunoassay testlari va reagentlari; hamda Q.E.D. tupurik alkogol testi. Kompaniya shuningdek, inson tupug'idan genetik materialni to'plash uchun Oragene va ORAcollect brendlari ostida genetik mahsulotlarni; siydik namunalari hajmini aniq to'plash uchun Colli-Pee to'plash moslamalarini; va HEMAcollect oqsil qon to'plash moslamasini taqdim etadi. Bundan tashqari, u ichak mikrobiomini profilini aniqlash uchun najas yoki axlat namunalari orqali mikrobli DNKni o'z-o'zini to'plash uchun OMNIgene GUT kabi mikrobiom mahsulotlarini; OMNIgene GUT DNA va RNA to'plash moslamalarini; OMNIgene SALIVA DNA va RNA to'plash moslamalarini; va inson axlat namunalari va bakterial jamoaning DNKni barqarorlashtirish uchun OMNIgene GUT Dx to'plash moslamasini taklif etadi. Bundan tashqari, u immunoassaylar va boshqa in vitro diagnostika testlari kabi boshqa diagnostika mahsulotlarini taklif etadi. Qo'shimcha ravishda, u xlamidiya traxomatis va neisseriya gonoreya uchun molekulyar o'z-o'zini tekshirishni ishlab chiqadi. U o'z mahsulotlarini klinik laboratoriyalar, shifoxonalar, klinikalarga, jamoat asosidagi tashkilotlarga va boshqa jamoat sog'liqni saqlash tashkilotlariga, distribyutorlarga, davlat agentliklariga, shifokorlar idoralariga, tijorat va sanoat korxonalariga, kasallik xavfini boshqarish, diagnostika, farmatsevtika, biotexnologiya va hamroh hayvonlar bozorlariga sotadi. Kompaniya 1987 yilda tashkil etilgan va shtab-kvartirasi Pensilvaniya shtatining Betlem shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Mr. David A. Rappaport C.F.A. | Senior Vice President of Corporate Development, Strategy & Integration |
| Mr. Jason Michael Plagman | Vice President of Investor Relations |
| Mr. Kenneth J. McGrath | Chief Financial Officer |
| Mr. Rafal Iwasiow Ph.D. | Sample Management Solutions R&D & Chief Scientist |
| Mr. Stefano Taucer | General Counsel & Corporate Secretary |
| Mr. Zachary Wert | Senior Vice President of Global Operations |
| Ms. Amy Steigerwalt | Senior Vice President of Human Resources |
| Ms. Carrie Eglinton Manner | President, CEO & Director |
| Ms. Karen Davies | Diagnostics R&D & Chief Technologist |
| Ms. Michele Anthony | Senior VP, Chief Accounting Officer, Controller & Assistant Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-11 | 8-K | osur-20260611.htm |
| 2026-06-03 | 8-K | osur-20260603.htm |
| 2026-05-08 | 10-Q | osur-20260331.htm |
| 2026-05-06 | 8-K | osur-20260506.htm |
| 2026-04-30 | DEF 14A | osur-20260430.htm |
| 2026-04-20 | PRE 14A | osur-20260420.htm |
| 2026-04-17 | DEFA14A | d46953ddefa14a.htm |
| 2026-04-17 | 8-K | d144249d8k.htm |
| 2026-03-30 | DEFA14A | d137435ddefa14a.htm |
| 2026-03-30 | 8-K | d138279d8k.htm |